Seminars in Perinatology
Volume 33, Issue 2 , Pages 116-123 , April 2009

The Role of the Anesthesiologist in Management of Obstetric Hemorrhage

  • George Gallos, MD
    • ,
  • Imre Redai, MD, FRCA
    • ,
  • Richard M. Smiley, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Richard M. Smiley, MD, PhD, Columbia University College of Physicians and Surgeons, Department of Anesthesiology, 630 West 168th Street PH-5, New York, NY

References 

  1. Baskett TF. James Blundell: The first transfusion of human blood. Resuscitation. 2002;52:229–233
  2. Fowler R, Gallagher JV, Isaacs SM, et al. The role of intraosseous vascular access in the out-of-hospital environment (resource document to NAEMSP position statement). Prehosp Emerg Care. 2007;11:63–66
  3. Duthie SJ, Ven D, Yung GL, et al. Discrepancy between laboratory determination and visual estimation of blood loss during normal delivery. Eur J Obstet Gynecol Reprod Biol. 1991;38:119–124
  4. Larsson C, Saltvedt S, Wiklund I, et al. Estimation of blood loss after cesarean section and vaginal delivery has low validity with a tendency to exaggeration. Acta Obstet Gynecol Scand. 2006;85:1448–1452
  5. Maslovitz S, Barkai G, Lessing JB, et al. Improved accuracy of postpartum blood loss estimation as assessed by simulation. Acta Obstet Gynecol Scand. 2008;87:929–934
  6. Moloney WC, Phillips LL, Pritchard JA, et al. Management of the obstetrical patient with hemorrhage due to an acute or subacute defibrination syndrome. Blood. 1959;14:1354–1367
  7. Carvalho JC, Balki M, Kingdom J, et al. Oxytocin requirements at elective cesarean delivery: A dose-finding study. Obstet Gynecol. 2004;104:1005–1010
  8. Balki M, Ronayne M, Davies S, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol. 2006;107:45–50
  9. Wray S. Uterine contraction and physiological mechanisms of modulation. Am J Physiol. 1993;264:C1–C18
  10. Henrich W, Surbek D, Kainer F, et al. Diagnosis and treatment of peripartum bleeding. J Perinat Med. 2008;36:467–478
  11. Thomas TA, Cooper GM. Deaths associated with anaesthesia. In:  Lewis G editors. Why Mothers Die 1997-1999 (Report from The Confidential Enquiries into Maternal Deaths in the United Kingdom). London: RCOG Press; 2001;p. 134–149
  12. Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesth. 2007;98:116–119
  13. Svanstrom MC, Biber B, Hanes M, et al. Signs of myocardial ischaemia after injection of oxytocin: A randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth. 2008;100:683–689
  14. Meirhaeghe A, Bauters C, Helbecque N, et al. The human G-protein beta3 subunit C825T polymorphism is associated with coronary artery vasoconstriction. Eur Heart J. 2001;22:845–848
  15. Weiniger CF, Elram T, Ginosar Y, et al. Anaesthetic management of placenta accreta: Use of a pre-operative high and low suspicion classification. J Anesth. 2005;60:1079–1084
  16. Hudon L, Belfort MA, Broome DR. Diagnosis and management of placenta percreta: A review. Obstet Gynecol Surv. 1998;53:509–517
  17. Mok M, Heidemann B, Dundas K, et al. Interventional radiology in women with suspected placenta accreta undergoing caesarean section. Int J Obstet Anesth. 2008;17:255–261
  18. O'Rourke N, McElrath T, Baum R, et al. Cesarean delivery in the interventional radiology suite: A novel approach to obstetric hemostasis. Anesth Analg. 2007;104:1193–1194
  19. Hawkins JL, Koonin LM, Palmer SK, et al. Anesthesia-related deaths during obstetric delivery in the United States, 1979-1990. Anesthesiology. 1997;86:277–284
  20. Karpati PC, Rossignol M, Pirot M, et al. High incidence of myocardial ischemia during postpartum hemorrhage. Anesthesiology. 2004;100:30–36
  21. Nall KS, Feldman B. Postpartum myocardial infarction induced by methergine. Am J Emerg Med. 1998;16:502–504
  22. Ribbing M, Reinecke H, Breithardt G, et al. Acute anterior wall infarct in a 31-year-old patient after administration of methylergometrin for peripartal vaginal hemorrhage. Herz. 2001;26:489–493
  23. Chestnut DH, Dewan DM, Redick LF, et al. Anesthetic management for obstetric hysterectomy: A multi-institutional study. Anesthesiology. 1989;70:607–610
  24. Chestnut DH, Redick LF. Continuous epidural anesthesia for elective cesarean hysterectomy. South Med J. 1985;78(1173):1168–1169
  25. Parekh N, Husaini SW, Russell IF. Caesarean section for placenta praevia: A retrospective study of anaesthetic management. Br J Anaesth. 2000;84:725–730
  26. Bhavani-Shankar K, Lynch EP, Datta S. Airway changes during Cesarean hysterectomy. Can J Anesth. 2000;47:338–341
  27. Comunale ME. A Laboratory evaluation of the level 1 rapid infuser (H1025) and the Belmont instrument fluid management system (FMS 2000) for rapid transfusion. Anesth Analg. 2003;97:1064–1069
  28. Sediame S, Zerah-Lancner F, d'Ortho MP, et al. Accuracy of the i-STAT bedside blood gas analyser. Eur Respir J. 1999;14:214–217
  29. Steinfelder-Visscher J, Teerenstra S, Gunnewiek JM, et al. Evaluation of the i-STAT point-of-care analyzer in critically ill adult patients. J Extra Corpor Technol. 2008;40:57–60
  30. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63:805–813
  31. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008;248:447–458
  32. Gunter OL, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: Identifying blood product ratios associated with improved survival. J Trauma. 2008;65:527–534
  33. Gyamfi C, Berkowitz RL. Responses by pregnant Jehovah's Witnesses on health care proxies. Obstet Gynecol. 2004;104:541–544
  34. Boonstra JG, Overbeeke MA, de Rijke YB, et al. [A pregnant woman with irregular erythrocyte antibodies for whom no compatible packed red blood cells were available]. Ned Tijdschr Geneeskd. 2005;149:2633–2636
  35. de Souza A, Permezel M, Anderson M, et al. Antenatal erythropoietin and intra-operative cell salvage in a Jehovah's witness with placenta praevia. Br J Obstet Gynaecol. 2003;110:524–526
  36. Fuhrer Y, Bayoumeu F, Boileau S, et al. [Evaluation of the blood quality collected by cell-saver during cesarean section]. Ann Fr Anesth Reanim. 1996;15:1162–1167
  37. Sullivan I, Faulds J, Ralph C. Contamination of salvaged maternal blood by amniotic fluid and fetal red cells during elective Caesarean section. Br J Anaesth. 2008;101:225–229
  38. Waters JH, Biscotti C, Potter PS, et al. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology. 2000;92:1531–1536
  39. Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: Analysis of t he national registry. Am J Obstet Gynecol. 1995;172:1158–1167discussion 1167-1169
  40. Bernstein HH, Rosenblatt MA, Gettes M, et al. The ability of the Haemonetics 4 Cell Saver System to remove tissue factor from blood contaminated with amniotic fluid. Anesth Analg. 1997;85:831–833
  41. Catling S, Joels L. Cell salvage in obstetrics: The time has come. Br J Obstet Gynaecol. 2005;112:131–132
  42. Camann W. Cell salvage during cesarean delivery: Is it safe and valuable? Maybe, maybe not!. Int J Obstet Anesth. 1999;8:75–76
  43. Allam J, Cox M, Yentis SM. Cell salvage in obstetrics. Int J Obstet Anesth. 2008;17:37–45
  44. Catling S. Blood conservation techniques in obstetrics: A UK perspective. Int J Obstet Anesth. 2007;16:241–249
  45. Wise A, Clark V. Strategies to manage major obstetric haemorrhage. Curr Opin Anaesthesiol. 2008;21:281–287
  46. Alfirevic Z, Elbourne D, Pavord S, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: The northern European registry 2000-2004. Obstet Gynecol. 2007;110:1270–1278
  47. Franchini M, Franchi M, Bergamini V, et al. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost. 2008;34:104–112
  48. Bouma LS, Bolte AC, van Geijn HP. Use of recombinant activated factor VII in massive postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol. 2008;137:172–177
  49. Welsh A, McLintock C, Gatt S, et al. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol. 2008;48:12–16
  50. Shander A, Rijhwani TS. Acute normovolemic hemodilution. Transfusion. 2004;44:26S–34S
  51. Estella NM, Berry DL, Baker BW, et al. Normovolemic hemodilution before cesarean hysterectomy for placenta percreta. Obstet Gynecol. 1997;90:669–670
  52. Nagy CJ, Wheeler AS, Archer TL. Acute normovolemic hemodilution, intraoperative cell salvage and PulseCO hemodynamic monitoring in a Jehovah's Witness with placenta percreta. Int J Obstet Anesth. 2008;17:159–163

PII: S0146-0005(08)00149-3

doi: 10.1053/j.semperi.2008.12.005

Seminars in Perinatology
Volume 33, Issue 2 , Pages 116-123 , April 2009

Article Tools